Alpha-synuclein inhibitors are a class of investigational therapies targeting the pathological aggregation of alpha-synuclein, a protein implicated in neurodegenerative diseases like Parkinson's ...

Lewy body diseases (LBDs) are a class of debilitating neurodegenerative disorders linked to the abnormal aggregation of the ...

Researchers have discovered how a cell surface protein called Aplp1 can play a role in spreading material responsible for Parkinson's disease from cell-to-cell in the brain.

A compound that showed early promise in the treatment of Parkinson's disease in fruit flies has also shown neuroprotective ...

Researchers concluded that the GLP-1RA showed no ability to slow disease progression in people living with Parkinson’s ...

BIIB143, also known as cemdomespib, was the most advanced asset to get the chop. Biogen acquired the Hsp90 modulator in 2023 through its buyout of Reata, a deal that centered on the FDA-approved ...

New research uncovers how declining protein clearance mechanisms with age lead to Alzheimer’s, Parkinson’s, and other ...

Scientists explore how the immune and nervous systems constantly communicate, influencing brain diseases, behavior, and ...

Parkinson's disease (PD) is the second most common neurodegenerative disorder, primarily characterized by motor dysfunction. Its pathological hallmark is the abnormal aggregation of α-synuclein ...

The symptoms of Parkinson’s disease could be reversed through injections of nanoparticles into the brain, which is a much less […] The post Parkinson’s Disease Can Be Reversed Through Injecting ...

Increased α-synuclein expression is implicated both in hereditary and sporadic Parkinson's disease. Proteomic analysis has identified a series of post-translational modifications in inclusions.